

Jae-Ho Yoon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3422993/publications.pdf>

Version: 2024-02-01

121
papers

1,320
citations

394421

19
h-index

526287

27
g-index

121
all docs

121
docs citations

121
times ranked

2006
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study. <i>International Journal of Hematology</i> , 2022, 115, 135-139.	1.6	5
2	Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML. <i>Blood</i> , 2022, 139, 1646-1658.	1.4	28
3	Prediction and recommendation by machine learning through repetitive internal validation for hepatic veno-occlusive disease/sinusoidal obstruction syndrome and early death after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2022, , .	2.4	3
4	Durable outcomes of double cord blood transplantation in adults with acute lymphoblastic leukemia: high-risk features for early and long-term mortality. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210767.	2.5	3
5	Daratumumab monotherapy in relapsed and refractory multiple myeloma patients with severely compromised forced expiratory volume in one second. <i>Blood Research</i> , 2022, 57, 76-80.	1.3	1
6	Prognostic role of the ratio of natural killer cells to regulatory T cells in patients with multiple myeloma treated with lenalidomide and dexamethasone. <i>Experimental Hematology</i> , 2022, 110, 60-68.	0.4	2
7	A retrospective comparison of salvage intensive chemotherapy <i>versus</i> venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML). <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210816.	2.5	7
8	Depth of Response to Intensive Chemotherapy Has Significant Prognostic Value among Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation with Intermediate or Adverse Risk at Diagnosis Compared to At-Risk Group According to European Leukemia Net 2017 Risk Stratification. <i>Cancers</i> , 2022, 14, 3199.	3.7	2
9	Impact of donor type on long-term graft-versus-host disease-free/relapse-free survival for adult acute lymphoblastic leukemia in first remission. <i>Bone Marrow Transplantation</i> , 2021, 56, 828-840.	2.4	7
10	Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: A prospective comparative study. <i>American Journal of Hematology</i> , 2021, 96, 98-109.	4.1	17
11	Differential effects of donor lymphocyte infusion upon treatment response and GVHD according to relapse level and donor sources in patients with myelodysplastic syndrome. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110437.	2.5	4
12	Prognostic Impacts of D816V KIT Mutation and Peri-Transplant RUNX1^ΔRUNX1T1 MRD Monitoring on Acute Myeloid Leukemia with RUNX1^ΔRUNX1T1. <i>Cancers</i> , 2021, 13, 336.	3.7	2
13	Natural-killer cell cytotoxicity as a diagnostic and prognostic marker for adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective phase II observational study. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110205.	2.5	3
14	Incidence and risk factors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1. <i>Bone Marrow Transplantation</i> , 2021, 56, 1603-1613.	2.4	11
15	The factors influencing clinical outcomes after leukapheresis in acute leukaemia. <i>Scientific Reports</i> , 2021, 11, 6426.	3.3	8
16	The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 424-432.	1.7	5
17	Non-inferior long-term outcomes of adults with Philadelphia chromosome-like acute lymphoblastic leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 1953-1963.	2.4	9
18	Prognostic values of D816V KIT mutation and peri-transplant CFBF-MYH11 MRD monitoring on acute myeloid leukemia with CFBF-MYH11. <i>Bone Marrow Transplantation</i> , 2021, 56, 2682-2689.	2.4	3

#	ARTICLE	IF	CITATIONS
19	Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an <sc>HLA</sc>-matched sibling donor. American Journal of Hematology, 2021, 96, 1441-1449.	4.1	7
20	Integrative Analysis of Gene Expression Data by RNA Sequencing for Differential Diagnosis of Acute Leukemia: Potential Application of Machine Learning. Frontiers in Oncology, 2021, 11, 717616.	2.8	6
21	Development and validation of a comorbidity index for predicting survival outcomes after allogeneic stem cell transplantation in adult patients with acute leukemia: a Korean nationwide cohort study. Blood Research, 2021, 56, 184-196.	1.3	5
22	Hepatic sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic cell transplantation: historical and current considerations in Korea. Korean Journal of Internal Medicine, 2021, 36, 1261-1280.	1.7	3
23	Comparable Outcomes After Alternative and Matched Sibling Donor Hematopoietic Stem Cell Transplantation and the Role of Molecular Measurable Residual Disease for Acute Myeloid Leukemia in Elderly Patients. Transplantation and Cellular Therapy, 2021, 27, 774.e1-774.e12.	1.2	12
24	Comparable Outcomes Between Unrelated and Haploidentical Stem Cell Transplantation in Adult Patients With Severe Aplastic Anemia. Transplantation, 2021, 105, 1097-1105.	1.0	4
25	Haploidentical Versus Cord Blood Stem Cell Transplantation As the Second Transplant for Relapsed Acute Myeloid Leukemia Patients after the First Stem Cell Transplantation. Blood, 2021, 138, 1849-1849.	1.4	0
26	Superior Survival Outcome of Blinatumomab Compared to Mitoxantrone-Etoposide-Cytarabine Salvage for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Propensity Score-Matched Cohort Analysis. Blood, 2021, 138, 2309-2309.	1.4	0
27	Comparison of Prognostic Impact between the European Leukemia Net (ELN) 2017 Risk Classification and Pre-Transplant WT1 expression in Patients Receiving Allogeneic Transplantation for Acute Myeloid Leukemia (AML). Blood, 2021, 138, 3459-3459.	1.4	0
28	Hepatic venoocclusive disease/sinusoidal obstruction syndrome with normal portal vein flow mimicking aggravated chronic hepatic GVHD following inotuzumab ozogamicin salvage therapy: a case report of pathologic-radiologic discrepancy. Therapeutic Advances in Hematology, 2021, 12, 204062072110661.	2.5	2
29	Impact of Epstein-Barr Virus on Peripheral T-Cell Lymphoma Not Otherwise Specified and Angioimmunoblastic T-Cell Lymphoma. Frontiers in Oncology, 2021, 11, 797028.	2.8	8
30	Excellent outcomes of hematopoietic stem cell transplantation with total nodal irradiation and antithymocyte globulin conditioning in severe aplastic anemia with advanced age and/or severe comorbidity. Bone Marrow Transplantation, 2020, 55, 1447-1450.	2.4	1
31	Experience of blinatumomab salvage for patients with acute lymphoblastic leukemia presenting with isolated extramedullary relapse after previous allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2020, 55, 1469-1472.	2.4	6
32	Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP. British Journal of Haematology, 2020, 188, 860-871.	2.5	5
33	HLA-mismatched donor and high ferritin level showed poor clinical outcomes after allogeneic hematopoietic cell transplantation in patients with advanced myelofibrosis. Therapeutic Advances in Hematology, 2020, 11, 204062072093693.	2.5	3
34	Experiences of allogeneic hematopoietic cell transplantation following non-myeloablative conditioning regimen in severely comorbid patients with myelofibrosis: case series with a patient presenting with extensive extramedullary hematopoiesis. Therapeutic Advances in Hematology, 2020, 11, 204062072093203.	2.5	2
35	Comparison of Myeloablative (CyTBI, BuCy) versus Reduced-Intensity (FluBu2TBI400) Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia Patients with Pretransplant Low WT1 Expression. Biology of Blood and Marrow Transplantation, 2020, 26, 2018-2026.	2.0	11
36	Non-myeloablative matched sibling stem cell transplantation with the optional reinforced stem cell infusion for patients with hemoglobinopathies. European Journal of Haematology, 2020, 105, 387-398.	2.2	4

#	ARTICLE	IF	CITATIONS
37	Specific donor HLA allotypes as predictors of cytomegalovirus disease risk in acute myeloid leukemia. <i>Hla</i> , 2020, 96, 445-455.	0.6	5
38	Outcomes of Haploidentical Stem Cell Transplantation using Total Body Irradiation (600 cGy) and Fludarabine with Antithymocyte Globulin in Adult Patients with Severe Aplastic Anemia: A Prospective Phase II Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1906-1914.	2.0	3
39	Effects of Hormone Replacement Therapy on Bone Mass After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3267-e3276.	3.6	4
40	Role of pretransplant anti- α CD33 antibody in matched sibling donor stem cell transplantation after reduced intensity conditioning for myelodysplastic syndrome. <i>European Journal of Haematology</i> , 2020, 104, 459-468.	2.2	1
41	Poor prognosis in patients with diffuse large B cell lymphomas with bone marrow involvement possessing chromosomal abnormalities, despite aggressive treatment. <i>Annals of Hematology</i> , 2020, 99, 557-570.	1.8	3
42	Safety and efficacy of arsenic trioxide and all-trans retinoic acid therapy in acute promyelocytic leukemia patients with a high risk for early death. <i>Annals of Hematology</i> , 2020, 99, 973-982.	1.8	6
43	Immuno-Target Therapy for Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Korean Journal of Medicine</i> , 2020, 95, 320-324.	0.3	0
44	A Phase 3 Trial of Thymoglobuline for Prevention of Chronic Gvhd in Transplantation from an HLA-Matched Sibling. <i>Blood</i> , 2020, 136, 32-32.	1.4	1
45	Effects of Delayed Treatment on Patients with Acute Myeloid Leukemia; Treatment Delay Matters in Younger Patients. <i>Blood</i> , 2020, 136, 19-20.	1.4	0
46	Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 63-72.	2.0	22
47	Autologous hematopoietic cell transplantation using dose-reduced intravenous busulfan, melphalan, and thiotepa for high-risk or relapsed lymphomas. <i>Bone Marrow Transplantation</i> , 2019, 54, 330-333.	2.4	6
48	Reactivation and dynamics of cytomegalovirus and Epstein-Barr virus after rabbit antithymocyte globulin and cyclosporine for aplastic anemia. <i>European Journal of Haematology</i> , 2019, 103, 433-441.	2.2	6
49	Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia. <i>Scientific Reports</i> , 2019, 9, 11935.	3.3	12
50	A case of central nervous system graft-versus-host disease following allogeneic stem cell transplantation. <i>International Journal of Hematology</i> , 2019, 110, 635-639.	1.6	12
51	Natural Killer Cell Function Tests by Flowcytometry-Based Cytotoxicity and IFN- γ Production for the Diagnosis of Adult Hemophagocytic Lymphohistiocytosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5413.	4.1	20
52	Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience. <i>Cancer Medicine</i> , 2019, 8, 6860-6870.	2.8	22
53	Improved survival outcomes and restoration of graft-versus-leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia. <i>Cancer Medicine</i> , 2019, 8, 501-514.	2.8	13
54	WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1925-1932.	2.0	31

#	ARTICLE	IF	CITATIONS
55	Alteration of the Intestinal Microbiota by Broad-Spectrum Antibiotic Use Correlates with the Occurrence of Intestinal Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1933-1943.	2.0	42
56	Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2019, 98, 1743-1753.	1.8	3
57	Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 345-355.e7.	0.4	4
58	Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD). <i>Bone Marrow Transplantation</i> , 2019, 54, 1361-1368.	2.4	20
59	Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation. , 2019, 7, 35.		20
60	Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. <i>Cancer Medicine</i> , 2019, 8, 7650-7659.	2.8	8
61	Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancy. <i>Haematologica</i> , 2019, 104, 269-276.	3.5	67
62	Considerations for monitoring minimal residual disease using immunoglobulin clonality in patients with precursor B-cell lymphoblastic leukemia. <i>Clinica Chimica Acta</i> , 2019, 488, 81-89.	1.1	7
63	CDKN2B downregulation and other genetic characteristics in T-acute lymphoblastic leukemia. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-15.	7.7	29
64	Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia. <i>Cancer</i> , 2019, 125, 873-883.	4.1	28
65	Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party. <i>Annals of Hematology</i> , 2019, 98, 151-158.	1.8	18
66	Predictive Role of Circulating Immune Cell Subtypes Early after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia. <i>International Journal of Stem Cells</i> , 2019, 12, 73-83.	1.8	23
67	Comparable Outcomes between Unrelated Donor (8/8 or 7/8 matched) and Haploidentical Donor for Allogeneic Stem Cell Transplantation in Adult Patients with Severe Aplastic Anemia. <i>Blood</i> , 2019, 134, 4619-4619.	1.4	0
68	Impact of an Additional Chromosome on the Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Acute Myeloid Leukemia in Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1621-1628.	2.0	3
69	Successful outcomes of second hematopoietic stem cell transplantation with total nodal irradiation and ATG conditioning for graft failure in adult patients with severe aplastic anemia. <i>Bone Marrow Transplantation</i> , 2018, 53, 1270-1277.	2.4	8
70	Prognostic Prediction Model for Second Allogeneic Stem-Cell Transplantation in Patients With Relapsed Acute Myeloid Leukemia: Single-Center Report. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e167-e182.	0.4	2
71	Matrix Metalloproteinase-9 in Monocytic Myeloid-Derived Suppressor Cells Correlate with Early Infections and Clinical Outcomes in Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 32-42.	2.0	28
72	Comparison of transplant-specific prognostic scoring systems in haploidentical transplantation for myelodysplastic syndrome. <i>European Journal of Haematology</i> , 2018, 101, 200-207.	2.2	0

#	ARTICLE	IF	CITATIONS
73	Circulating CD3 ⁺ CD4 ⁺ CD161 ⁺ Cells Are Associated with Early Complications after Autologous Stem Cell Transplantation in Multiple Myeloma. <i>BioMed Research International</i> , 2018, 2018, 1-8.	1.9	3
74	Low frequency of CD3 ⁺ CD4 ⁺ CD161 ⁺ T cells correlates with the occurrence of infections in refractory/relapsed multiple myeloma patients receiving lenalidomide plus low-dose dexamethasone treatment. <i>Annals of Hematology</i> , 2018, 97, 2163-2171.	1.8	6
75	Optimal conditioning regimen for haploidentical stem cell transplantation in adult patients with acquired severe aplastic anemia: Prospective de-escalation study of TBI and ATG dose. <i>American Journal of Hematology</i> , 2018, 93, 1368-1375.	4.1	12
76	Association of MICA and MICB polymorphisms with the susceptibility of leukemia in Korean patients. <i>Blood Cancer Journal</i> , 2018, 8, 58.	6.2	9
77	Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapy. <i>Oncotarget</i> , 2018, 9, 5823-5833.	1.8	1
78	Specific Donor Human Leukocyte Antigen (HLA) Allotypes and CMV IgG Serology Status Predict the Risk of Cytomegalovirus-Related Disease in Acute Myeloid Leukemia Patients Who Received Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 2076-2076.	1.4	0
79	Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas. <i>Hematological Oncology</i> , 2017, 35, 17-24.	1.7	9
80	Clinical Outcome of Autologous Hematopoietic Cell Transplantation in Adult Patients with Acute Myeloid Leukemia: Who May Benefit from Autologous Hematopoietic Cell Transplantation?. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 588-597.	2.0	20
81	High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RAR α after anthracycline-based chemotherapy: a single-center cohort study. <i>Journal of Hematology and Oncology</i> , 2017, 10, 30.	17.0	15
82	Clinical significance of pre-transplant circulating CD ³ ⁺ CD ⁴ ⁺ CD ¹⁶¹ ⁺ cell frequency on the occurrence of neutropenic infections after allogeneic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2017, 19, e12643.	1.7	15
83	Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1498-1508.	2.0	16
84	Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 595-603.	0.4	2
85	Outcomes of allogeneic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria with or without aplastic anemia. <i>European Journal of Haematology</i> , 2017, 99, 336-343.	2.2	16
86	Characteristics and Survival Outcome Analysis of Extramedullary Involvement in Adult Patients With t(8;21) Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 38-45.e2.	0.4	4
87	Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts. <i>Oncotarget</i> , 2017, 8, 12342-12354.	1.8	27
88	Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia. <i>Blood Research</i> , 2017, 52, 174.	1.3	7
89	Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types. <i>Oncotarget</i> , 2017, 8, 41590-41604.	1.8	19
90	Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 983-994.	4.2	21

#	ARTICLE	IF	CITATIONS
91	Negative Impact of Unidirectional Host-versus-Graft Killer Cell Immunoglobulin-like Receptor Ligand Mismatch on Transplantation Outcomes after Unmanipulated Haploidentical Peripheral Blood Stem Cell Transplantation for Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 316-323.	2.0	10
92	Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission. <i>Oncotarget</i> , 2016, 7, 17230-17241.	1.8	28
93	Clinical manifestations of autoimmune disease-related non-Hodgkin lymphoma: a Korean single-center, retrospective clinical study. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 944-952.	1.7	1
94	Efficacy and Safety of Promace-Cytabom Regimen with Sandwiched Radiotherapy Method in the Treatment of Newly Diagnosed, Stage IE to IIE, Extranodal NK/T-Cell Lymphoma, Nasal Type. <i>Blood</i> , 2016, 128, 3006-3006.	1.4	0
95	Low Frequency of CD161+CD4+ T Cells Correlate with the Occurrence of Infections in Refractory/Relapsed Multiple Myeloma Patients Receiving Lenalidomide Plus Low-Dose Dexamethasone Treatment. <i>Blood</i> , 2016, 128, 5621-5621.	1.4	0
96	Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome. <i>Journal of Hematology and Oncology</i> , 2015, 8, 118.	17.0	29
97	Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal <scp>AML</scp> and identification of high-risk subgroup using <scp><i>W</i></scp> <scp><i>T1</i></scp> expression in association with <scp><i>N</i></scp> <scp><i>PM1</i></scp> and <scp><i>FLT3</i></scp> mutations. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 489-499.	2.8	11
98	<i>SOCS1</i> and <i>SOCS3</i> are expressed in mononuclear cells in human cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation. <i>Blood Research</i> , 2015, 50, 40.	1.3	5
99	CD161+ T Cells as Predictive Markers for Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 421-428.	2.0	14
100	Wilms Tumor Gene 1 Expression as a Predictive Marker for Relapse and Survival after Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 460-467.	2.0	16
101	Feasible Outcomes of T Cell-replete Haploidentical Stem Cell Transplantation with Reduced-Intensity Conditioning in Patients with Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 342-349.	2.0	23
102	Clinical outcomes of venous thromboembolism with dalteparin therapy in multiple myeloma patients. <i>Thrombosis Research</i> , 2015, 136, 974-979.	1.7	11
103	Equivalent Outcome of Autologous Stem Cell Transplantation and Reduced Intensity Conditioning Stem Cell Transplantation in Acute Myeloid Leukemia Patients with t(8;21). <i>Acta Haematologica</i> , 2015, 133, 266-276.	1.4	12
104	A Well-Tolerated Regimen of 800 cGy TBI-Fludarabine-Busulfan-ATG for Reliable Engraftment after Unmanipulated Haploidentical Peripheral Blood Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 119-129.	2.0	36
105	Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 362.	1.7	12
106	Bone Marrow Plasma Cell Assessment before Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	9
107	Comparative analysis of post-transplant lymphoproliferative disorder after kidney transplantation versus hematopoietic stem cell transplantation. <i>Transplant International</i> , 2014, 27, 721-732.	1.6	9
108	Stratification of de novo Adult Acute Myelogenous Leukemia with Adverse-Risk Karyotype: Can We Overcome the Worse Prognosis of Adverse-Risk Group Acute Myelogenous Leukemia with Hematopoietic Stem Cell Transplantation?. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 80-88.	2.0	8

#	ARTICLE	IF	CITATIONS
109	Implication of higher BAALC expression in combination with other gene mutations in adult cytogenetically normal acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 110-120.	1.3	10
110	Clinico-Immunobiologic Study By a Prospective Open-Label Clinical Trial of Deferasirox before & after Allogeneic HSCT in Adult Patients with AML - Preliminary Analysis Focusing on Outcomes with Immunocyte Subsets (I) -. <i>Blood</i> , 2014, 124, 2543-2543.	1.4	0
111	Efficiency of Homing and Engraftment Is Higher in VEGFR-3+CD34+CD38- Cells Than in VEGFR-3-CD34+CD38- Cells in Leukemic Patients. <i>Blood</i> , 2014, 124, 4782-4782.	1.4	0
112	Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission. <i>American Journal of Hematology</i> , 2013, 88, 634-641.	4.1	32
113	Normal karyotype mosaicism in adult AML patients with adverse-risk and undefined karyotype: preliminary report of treatment outcomes after hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2013, 97, 773-781.	1.6	3
114	The efficacy of rabbit antithymocyte globulin with cyclosporine in comparison to horse antithymocyte globulin as a first-line treatment in adult patients with severe aplastic anemia: a single-center retrospective study. <i>Annals of Hematology</i> , 2013, 92, 817-824.	1.8	40
115	Serial Measurement of WT1 Expression and Decrement Ratio Until Hematopoietic Cell Transplantation as a Marker of Residual Disease in Patients with Cytogenetically Normal Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 958-966.	2.0	22
116	BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding factor-positive AML. <i>European Journal of Haematology</i> , 2013, 91, 112-121.	2.2	20
117	Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status. <i>American Journal of Hematology</i> , 2013, 88, 1074-1081.	4.1	17
118	Response to pretransplant hypomethylating agents influences the outcome of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2013, 90, 111-120.	2.2	17
119	Hepatic veno-occlusive disease resulting in tacrolimus toxicity after allogeneic hematopoietic stem cell transplantation. <i>Blood Research</i> , 2013, 48, 55.	1.3	8
120	Molecular and Cytogenetic Risk Stratification For Core-Binding Factor-Positive Adult AML With Analysis Of Post-Remission Treatment Outcomes Including Transplantation. <i>Blood</i> , 2013, 122, 1301-1301.	1.4	0
121	Comparison of Allogeneic Stem Cell Transplantation from Familial-Mismatched/Haploidentical Donors and from Unrelated Donors in Adults with High-Risk Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1552-1563.	2.0	39